Disease Characteristics of R-CAD (NCT07239921) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Disease Characteristics of R-CAD
52 participantsStarted 2025-11
Plain-language summary
The present case-control study is designed to investigate the disease characteristics of rapidly progressive coronary artery disease (R-CAD) by comparing the demographics, clinical features, lab results, imaging findings, and prior treatment between patients in the case group (approximately 34 patients with R-CAD) and those in the control group (approximately 18 patients with non-rapidly progressive coronary artery disease \[NR-CAD\]).
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. 18 years of age or older, male or female.
✓. Negative results of urine or blood pregnancy test for females with childbearing potential (not post-menopausal or surgically sterile).
✓. Prior history of coronary revascularization (PCI or CABG).
✓. Receiving standard treatment for secondary prevention of AS-CAD after the latest coronary revascularization.
✓. Rapidly progressive myocardial ischemia leading to hospitalization and/or coronary revascularization:
✓. Typical symptoms of angina (Canadian Cardiovascular Society \[CCS\] classification III-IV) and non-invasive evidence of myocardial ischemia; and
✓. Occurred within 6 months of the latest ischemia-driven hospitalization and/or coronary revascularization.
✓. Rapidly progressive coronary lesions leading to myocardial ischemia:
Exclusion criteria
✕. Receiving immunosuppressive therapy within 6 months.
✕. Coronary restenosis due to mechanical factors (stent under-expansion, stent mal-apposition, stent rupture, et al).
✕. Other moderate to severe heart diseases (congenital heart disease, valvular heart disease, myocarditis, cardiomyopathy, pericardial diseases, pulmonary hypertension, heart failure, arrhythmia, et al).
What they're measuring
1
Elevated ESR or hs-CRP
Timeframe: From 30 days before enrollment up to 14 days after enrollment, but before the initiation of immunosuppressive therapy.